학술논문
Oral decitabine–cedazuridine versus intravenous decitabine for myelodysplastic syndromes and chronic myelomonocytic leukaemia (ASCERTAIN): a registrational, randomised, crossover, pharmacokinetics, phase 3 study
Document Type
Article
Author
Garcia-Manero, G.; Kantarjian, H.; McCloskey, J.; Griffiths, E.A.; Yee, K.W.L.; Zeidan, A.M.; Al-Kali, A.; Deeg, H.J.; Patel, P.A.; Sabloff, M.; Keating, M.-M.; Zhu, N.; Gabrail, N.Y.; Fazal, S.; Maly, J.; Odenike, O.; DeZern, A.E.; O'Connell, C.L.; Roboz, G.J.; Busque, L.; Buckstein, R.; Amin, H.; Randhawa, J.; Leber, B.; Shastri, A.; Dao, K.-H.; Oganesian, A.; Hao, Y.; Keer, H.N.; Azab, M.; Savona, M.R.
Source
In: The Lancet Haematology . (The Lancet Haematology, January 2024, 11(1):e15-e26)
Subject
Language
English
ISSN
23523026